N-acetylglucosamine

N-乙酰氨基葡萄糖

Report date: 2026/04/27 20:02:09
NME

Base Information

Drug NameN-acetylglucosamine
Drug Alias NameN-乙酰葡糖胺艾替沙敏NP-101
ClassificationSmall molecules > Carbohydrate
Mechanisms of ActionLeukocyte elastase inhibitors
TargetsLeukocyte elastase
Therapy Area/IndicationsSolid tumoursSevere Acute MalnutritionIrritable Bowel Syndrome +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryZambiaUnited StatesZimbabwe +[4] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPending
Originator CompaniesSuzhou Bawei Medicine Development & Research Institute Co LtdArmy Medical University, ChinaDsm Jiangshan Pharmaceutical (Jiangsu) Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesJohns Hopkins UniversityThe University Of Texas MD Anderson Cancer Center
Inactive CompaniesArmy Medical University, ChinaUniversity Of FloridaQueen Mary University Of London +[5] 
Active IndicationsSolid tumoursCrohn Disease
Inactive IndicationsSevere Acute MalnutritionIrritable Bowel SyndromeCarcinoma, Hepatocellular

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG